Study of the Antiviral Activity of Drugs and Their Combination Against the Influenza A Virus

Relevance. The problem of prevention and treatment of influenza remains relevant due to the consistently high incidence rate of the disease in the population of all age groups, especially children and the elderly. Antiviral drugs have become the most important tools in the fight against influenza viruses. The main problem is the search and development of new antiviral drugs that do not have side effects. The aim of the present study is to investigate the effect of a new synthetic drug candidate based on adamantane (NMG 1110) and its combination with ribavirin on the reproduction of influenza A virus in MDCK cell culture. The aim of the present study is to investigate the effects of drugs and their combinations on the reproduction of influenza A virus in MDCK cell culture. Materials and methods. Determination of cytotoxicity and antiviral activity of drugs on MDCK cell line for influenza A(H3N2)/Aichi/1/68 virus at different schemes of drug introduction into cells: immediately after infection, 2 hours after infection, 4 hours after virus infection of cells. Results. It was found that the drugs were low-toxic for MDCK cell culture at the studied concentrations. Using the influenza A(H3N2)/Aichi/1/68 virus model, it was shown that the time of application of the studied samples did not affect the reproduction of the virus in cell culture. The NMG1110 preparation exhibits high antiviral activity at a concentration of 9.7 µg/ml with the chemotherapeutic index of 16.0. At the same time, ribavirin showed a lower effect with a chemotherapeutic index of 8.0. There is a significant suppression of virus reproduction with the combined use of the preparations. A pronounced antiviral effect of the additive nature is observed in the combination of ribavirin and the drug candidate NMG 1110.

1. Javanian M., Barary M., Ghebrehewet S., Koppolu V., Vasigala V., Ebrahimpour S. A brief review of influenza virus infection. J Med Virol. 2021 Aug; 93 (8): 4638–4646. doi: 10.1002/jmv.26990. Epub 2021 Apr 14. PMID: 33792930.

2. Lyubimov I. I., Isaeva E. I., Vetrova E. N., Lavrova A. V., Greckaya N. M., Serkov I. V., Bezuglov V. V., Galegov G. A. Study of the antiviral activity of adamantane-containing chemical compounds. Antibiotiki i Khimioter = Antibiotics and Chemotherapy. Antibiotiki i himioter. 2022; 67: 7–8: 19–23. doi: https://doi.org/10.37489/0235-2990-2022-67-7-8-19-23. (in Russian)

3. Sekiya T., Ohno M., Nomura N., Handabile C., Shingai M., Jackson D. C., Brown L.E., Kida H. Selecting and Using the Appropriate Influenza Vaccine for Each Individual. Viruses. 2021 May 24; 13 (6): 971. doi: 10.3390/v13060971. PMID: 34073843; PMCID: PMC8225103.

4. Nypaver C., Dehlinger C., Carter C. Influenza and Influenza Vaccine: A Review. J Midwifery Womens Health. 2021 Jan; 66 (1): 45–53. doi: 10.1111/jmwh.13203. Epub 2021 Feb 1. PMID: 33522695; PMCID: PMC8014756.

5. Grigoryan S.S., Kovalenko A. L., Isaeva E. I., Vetrova E. N., Tyusheva V. V. Cikloferon i virus grippa A (H3N2) v kul'turah kletok. Dejstvie cikloferona na reprodukciyu virusa grippa A (H3N2) v predobrabotannyh do zarazheniya kul'turah kletok. Eksperimental'naya i Klinicheskaya Farmakologiya. 2018; 81 (11): 26с31. doi: https://doi.org/10.30906/0869-2092-2018-81-11-26-31(in Russian)

6. Zarubaev V. V., Krivickaya V. Z., Nebol'sin V. E., Kiselev O. I. Eksperimental'noe izuchenie protivovirusnoj aktivnosti Ingavirina v otnoshenii virusa paragrippa cheloveka. Antibiot Khimioter = Antibiotics and Chemotherapy. 2010; 55 (7–8): 13–16. (in Russian)

7. Kumari R., Sharma S. D., Kumar A., Ende Z., Mishina M., Wang Y., Falls Z., Samudrala R., Pohl J., Knight P. R., Sambhara S. Antiviral Approaches against Influenza Virus. Clin Microbiol Rev. 2023 Mar 23; 36 (1): e0004022. doi: 10.1128/cmr.00040-22. Epub 2023 Jan 16. PMID: 36645300; PMCID: PMC10035319.

8. Afanasyeva O. I., Esaulenko E. V. A look at the effectiveness of the release of active antivirals in treatment of influenza and ARVI in the light of evidence-based medicine. Consilium Medicum. 2016; 18 (3): 18–21. (in Russian)

9. Dobrovolskiy A. V. Approaches to clinical development of combination medicines in the Russian Federation and the Eurasian Economic Union in view of the requirements of the current legislation. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientifi c Centre for Expert Evaluation of Medicinal Products. 2019; 9(1): 14–27. doi: https://doi.org/10.30895/1991-2919-2019-9-1-14-27 (In Russ)

10. Sawamura R., Sun Y., Yasukawa K., Shimizu T., Watanabe W., Kurokawa M. Antiviral activities of diarylheptanoids against influenza virus in vitro. J Nat Med. 2010 Jan; 64 (1): 117–120. doi: 10.1007/s11418-009-0372-2.

11. Eisfeld A. J., Neumann G., Kawaoka Y. Influenza A virus isolation, culture and identification. Nat Protoc. 2014 Nov; 9 (11): 2663–2681. doi: 10.1038/nprot.2014.180.

12. Rukovodstvo po eksperimental'nomu (doklinicheskomu) izucheniyu novyh farmakologicheskih veshchestv. R.U. Habriev (ed.). Moscow: OAO Izdatel'stvo «Medicina». 2012; 832. (in Russian)

13. Reed L., Muench H. A simple method of estimating 50% endpoints. Amer J Hygiene. 1938; 27: 493–497.